Cite
HARVARD Citation
Rischin, D. et al. (n.d.). 97P Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti–PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC). Annals of oncology. p. . [Online].